tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Can-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
PremiumThe FlyCan-Fite price target lowered to $4.50 from $12 at Alliance Global Partners
3M ago
Can-Fite BioPharma trading resumes
Premium
The Fly
Can-Fite BioPharma trading resumes
3M ago
Can-Fite BioPharma announces $3.0M registered direct offering of ADSs
Premium
The Fly
Can-Fite BioPharma announces $3.0M registered direct offering of ADSs
3M ago
Can-Fite BioPharma to initiate Phase II study in Lowe Syndrome
PremiumThe FlyCan-Fite BioPharma to initiate Phase II study in Lowe Syndrome
4M ago
Can-Fite announces FDA approved compassionate use treatment of Namodenoson
Premium
The Fly
Can-Fite announces FDA approved compassionate use treatment of Namodenoson
4M ago
Can-Fite’s Namodenoson Shows Promise in Treating Liver Cirrhosis
Premium
Company Announcements
Can-Fite’s Namodenoson Shows Promise in Treating Liver Cirrhosis
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100